Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.
Phase 1
18 Years
50 Years
18 Years
50 Years
Not Enrolling
Both
Healthy
Both
Healthy
Trial Information
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.
Inclusion Criteria:
- Healthy
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Measure:
Pharmacokinetics; safety and tolerability; influence of food on the same.
Principal Investigator
Puma
Investigator Role:
Study Director
Investigator Affiliation:
Biotechnology
Authority:
United States: Food and Drug Administration
Study ID:
3144A1-107
NCT ID:
NCT00366600
Start Date:
July 2006
Completion Date:
December 2006
Related Keywords:
- Healthy
- Breast Cancer
- Health
- Pharmacokinetics
- healthy subjects
Name | Location |
|---|---|
| Seattle, Washington 98195 |
